Skip to content

Noval biomarkers screening for bronchiectasis

Noval biomarkers screening for bronchiectasis early diagnosis, assessment of severity level and exacerbation through muti-omics technologies

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024833
Enrollment
Unknown
Registered
2019-07-29
Start date
2019-08-05
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchiectasis

Interventions

Gold Standard:Confirmed diagnosis of bronchiectasis by HRCT?
technology

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged older than 18 years; 2. Confirmed diagnosis of bronchiectasis by HRCT within 12 months; 3. Able to expectoration spontaneously at baseline; 4. Clinically stable and has no exacerbations for at least four months prior to recruitment; 5. no antibiotic therapy for at least four months.

Exclusion criteria

Exclusion criteria: 1. Traction bronchiectasis; 2. Lesions of small area of pulmonary segments at HRCT; 3. Diagnosis of other pulmonary diseases such as asthma, COPD, pneumonia and so on; 4. Respiratory symptoms (including cough, sputum production, recurrent exacerbations) not predominantly the result of bronchiectasis in the opinion of the PI; 5. Diagnosis of digestive system diseases, hyperpiesia, hyperglycaemia or hyperlipemia; 6. Any history of cancers, severe heart disease(such as malignant arrhythmia, acute MI) or participants receiving LTOT; 7. Any history of serious active disease affecting survival outcomes within 12 months such as lung transplantation; 8. Serious, uncontrolled disease (including serious psychological disorders) likely to interfere with the study or impact on subject safety; 9. Prescription of either oral or intravenous antibiotic therapy in the preceding 4 weeks; 10. Have evidence of alcohol or drug abuse; 11. Unable to complete the required procedures for any reason.

Design outcomes

Primary

MeasureTime frame
genomics;transcriptomics;transcriptomics;protomics;lipidomics;microbiome;immunohistochemical analysis;glycomics;virus;fungi;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactFuqiang Wen

West China Hospital, Sichuan University

wenfuqiang@126.com+86 18980601258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026